DataSheet_1_The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China.docx

ObjectiveThe aim of this study was to investigate the cost-effectiveness of serplulimab versus regorafenib in previously treated unresectable or metastatic microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) colorectal cancer in China.MethodsFrom the perspective of China’s health-care system, a Markov model with three health states (progression free, progression, death) was developed for estimating the costs and health outcomes of serplulimab and regorafenib. Data for unanchored matching-adjusted indirect comparison (MAIC), standard parametric survival analysis, the mixed cure model, and transition probabilities calculation were obtained from clinical trials (ASTRUM-010 and CONCUR). Health-care resource utilization and costs were derived from government-published data and expert interviews. Utilities used to calculate quality-adjusted life years (QALYs) were obtained from clinical trials and literature reviews. The primary outcome was the incremental cost-effectiveness ratio (ICER) expressed as cost/QALY gained. Four scenarios were considered in scenario analysis: (a) using original survival data without conducting MAIC; (b) limiting the time horizon to the follow-up time of the clinical trial of serplulimab; (c) adopting a fourfold increase in the risk of death; and (d) applying utilities from two other sources. One-way sensitivity analysis and probabilistic sensitivity analysis were also performed to assess the uncertainty of the results.ResultsIn the base-case analysis, serplulimab provided 6.00 QALYs at a cost of $68,722, whereas regorafenib provided 0.69 QALYs at a cost of$40,106. Compared with that for treatment with regorafenib, the ICER for treatment with serplulimab was $5,386/QALY, which was significantly lower than the triple GDP per capita of China in 2021 ($30,036), which was the threshold used to define the cost-effectiveness. In the scenario analysis, the ICERs were $6,369/QALY,$20,613/QALY, $6,037/QALY,$4,783/QALY, and $6,167/QALY, respectively. In the probabilistic sensitivity analysis, the probability of serplulimab being cost-effective was 100$30,036/QALY.ConclusionCompared with regorafenib, serplulimab is a cost-effective treatment for patients with previously treated unresectable or metastatic MSI-H/dMMR colorectal cancer in China.</p

Soluble Imide-Bridged Polypentamethyltrisiloxane (IBPPMS) with Rationally Designed Ladder-like Structure for O₂/N₂ Permselectivity

Oxygen/nitrogen (O2/N2) permselective membranes are widely used in both industrial and medical applications. Polysiloxane is one of the most important membrane materials with high oxygen permeability, but its poor capacities for gas separation and membrane formation limit its practical use. In this study, a soluble imide-bridged polypentamethyl­trisiloxane (IBPPMS) with a high molecular weight (Mn = 8.91 × 104) was designed and synthesized via a hydrosilylation reaction between polypentamethyl­trisiloxane (PPMS) and N,N′-bis­(3-allyl)­pyromellitic diimide (DAI) in NMP under Karstedt’s catalysis. The ladder-like structure of sample was analyzed and determined through infrared spectroscopy (IR), nuclear magnetic resonance spectroscopy (1H NMR and 29Si NMR), and gel permeation chromatography (GPC). The IBPPMS membrane displays excellent thermal resistance. Furthermore, its O2 permeation performance achieves 47.1 barrer, and its separation factor reaches 7.11 with a feeding proportion of 50% each for O2/N2, exceeding the 2008 Roberson upper bound. Thus, it appears that membranes can achieve high selectivity and permeability as well as exhibit desirable thermal properties and sufficient stability when separating numerous industrial significant gas mixtures. The discovery of trapezoidal structural backbone of this polymer materials substantially affects their separation properties and sustained performances

Data_Sheet_1_Protective Role of L-3-n-Butylphthalide in Cognitive Function and Dysthymic Disorders in Mouse With Chronic Epilepsy.PDF

<p>Epilepsy is a common neurological disease with recurrent seizures and neurobehavioral comorbidities, including cognitive impairment and psychiatric disorders. Recent studies suggest that L-3-n-butylphthalide (NBP), an extract from the seeds of Apium graveolens Linn. (Chinese celery), ameliorates cognitive dysfunction in ischemia and/or Alzheimer’s disease animal models. However, little is known about the role of NBP in epilepsy and the associated comorbidities. Here, using a pilocarpine-induced chronic epileptic mouse model, we found that NBP supplement not only alleviated seizure severity and abnormal electroencephalogram, but also rescued cognitive and emotional impairments in these epileptic mice. The possible underlying mechanisms may be associated with the protective role of NBP in reducing neuronal loss and in restoring the expression of neural synaptic proteins such as postsynaptic density protein 95 (PSD95) and glutamic acid decarboxylase 65/67 (GAD65/67). In addition, NBP treatment increased the transcription of neuroprotective factors, brain-derived neurotrophic factor and Klotho. These findings suggest that NBP treatment may be a potential strategy for ameliorating epileptogenesis and the comorbidities of cognitive and psychological impairments.</p